| The role of BRAF V600 mutation in melanoma PA Ascierto, JM Kirkwood, JJ Grob, E Simeone, AM Grimaldi, M Maio, ... Journal of translational medicine 10, 1-9, 2012 | 944 | 2012 |
| Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy AM Grimaldi, E Simeone, D Giannarelli, P Muto, S Falivene, V Borzillo, ... Oncoimmunology 3 (5), e28780, 2014 | 402 | 2014 |
| Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab M Capone, D Giannarelli, D Mallardo, G Madonna, L Festino, AM Grimaldi, ... Journal for immunotherapy of cancer 6, 1-7, 2018 | 367 | 2018 |
| Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma E Simeone, G Gentilcore, D Giannarelli, AM Grimaldi, C Caracò, ... Cancer immunology, immunotherapy 63, 675-683, 2014 | 275 | 2014 |
| Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination I Melero, AM Grimaldi, JL Perez-Gracia, PA Ascierto Clinical Cancer Research 19 (5), 997-1008, 2013 | 228 | 2013 |
| Efficacy and safety of ipilimumab 3 mg/kg in patients with pretreated, metastatic, mucosal melanoma M Del Vecchio, L Di Guardo, PA Ascierto, AM Grimaldi, VC Sileni, ... European Journal of Cancer 50 (1), 121-127, 2014 | 159 | 2014 |
| Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use PA Ascierto, E Simeone, D Giannarelli, AM Grimaldi, A Romano, ... Journal of translational medicine 10, 1-8, 2012 | 153 | 2012 |
| MEK inhibitors in the treatment of metastatic melanoma and solid tumors AM Grimaldi, E Simeone, L Festino, V Vanella, M Strudel, PA Ascierto American journal of clinical dermatology 18, 745-754, 2017 | 134 | 2017 |
| Single-cell RNA sequencing analysis: a step-by-step overview S Slovin, A Carissimo, F Panariello, A Grimaldi, V Bouché, G Gambardella, ... RNA bioinformatics, 343-365, 2021 | 115 | 2021 |
| Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized … PA Ascierto, M Mandalà, PF Ferrucci, M Guidoboni, P Rutkowski, ... Journal of Clinical Oncology 41 (2), 212-221, 2023 | 114 | 2023 |
| Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme V Chiarion Sileni, J Pigozzo, PA Ascierto, AM Grimaldi, M Maio, ... Journal of Experimental & Clinical Cancer Research 33, 1-7, 2014 | 111 | 2014 |
| Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab S Morello, M Capone, C Sorrentino, D Giannarelli, G Madonna, ... Journal of translational medicine 15, 1-9, 2017 | 97 | 2017 |
| CXCR4 and CXCR7 transduce through mTOR in human renal cancer cells C Ieranò, S Santagata, M Napolitano, F Guardia, A Grimaldi, E Antignani, ... Cell death & disease 5 (7), e1310-e1310, 2014 | 91 | 2014 |
| Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy V Montesarchio, R Parrella, C Iommelli, A Bianco, E Manzillo, F Fraganza, ... Journal for immunotherapy of cancer 8 (2), 2020 | 90 | 2020 |
| Assessing a novel immuno-oncology-based combination therapy: Ipilimumab plus electrochemotherapy N Mozzillo, E Simeone, L Benedetto, M Curvietto, D Giannarelli, ... Oncoimmunology 4 (6), e1008842, 2015 | 84 | 2015 |
| Combination treatment of patients with BRAF-mutant melanoma: a new standard of care E Simeone, AM Grimaldi, L Festino, V Vanella, M Palla, PA Ascierto BioDrugs 31, 51-61, 2017 | 76 | 2017 |
| Aligning single-cell developmental and reprogramming trajectories identifies molecular determinants of myogenic reprogramming outcome D Cacchiarelli, X Qiu, S Srivatsan, A Manfredi, M Ziller, E Overbey, ... Cell Systems 7 (3), 258-268. e3, 2018 | 71 | 2018 |
| Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity A Inno, G Metro, P Bironzo, AM Grimaldi, E Grego, V Di Nunno, V Picasso, ... Tumori Journal 103 (5), 405-421, 2017 | 67 | 2017 |
| IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients R Tallerico, CM Cristiani, E Staaf, C Garofalo, R Sottile, M Capone, ... Oncoimmunology 6 (2), e1261242, 2017 | 65 | 2017 |
| The role of MEK inhibitors in the treatment of metastatic melanoma AM Grimaldi, E Simeone, PA Ascierto Current opinion in oncology 26 (2), 196-203, 2014 | 58 | 2014 |
